98 related articles for article (PubMed ID: 15590188)
1. Effect of irradiation on neovascularization in rat skinfold chambers: implications for clinical trials of low-dose radiotherapy for wet-type age-related macular degeneration.
Hori K; Saito S; Tamai M
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1564-71. PubMed ID: 15590188
[TBL] [Abstract][Full Text] [Related]
2. Treatment of age-related subfoveal neovascular membranes by teletherapy: results of a non-randomized study.
Subaşi M; Akmansu M; Or M
Radiat Med; 1999; 17(2):169-73. PubMed ID: 10399787
[TBL] [Abstract][Full Text] [Related]
3. Long-term results after external radiotherapy in age-related macular degeneration. A prospective study.
Prettenhofer U; Haas A; Mayer R; Stranzl H; Oechs A; Hackl A
Strahlenther Onkol; 2004 Feb; 180(2):91-5. PubMed ID: 14762661
[TBL] [Abstract][Full Text] [Related]
4. Overview of radiation trials for age-related macular degeneration.
Kaiser PK
Retina; 2009 Jun; 29(6 Suppl):S34-5. PubMed ID: 19553797
[TBL] [Abstract][Full Text] [Related]
5. Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD.
Avila MP; Farah ME; Santos A; Kapran Z; Duprat JP; Woodward BW; Nau J
Retina; 2009 Feb; 29(2):157-69. PubMed ID: 19202425
[TBL] [Abstract][Full Text] [Related]
6. Proton beam irradiation for neovascular age-related macular degeneration.
Zambarakji HJ; Lane AM; Ezra E; Gauthier D; Goitein M; Adams JA; Munzenrider JE; Miller JW; Gragoudas ES
Ophthalmology; 2006 Nov; 113(11):2012-9. PubMed ID: 16935343
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic effects on retinal oxygen saturation, blood flow, and electrophysiological function in patients with neovascular age-related macular degeneration.
Tsuchihashi T; Mori K; Peyman G; Shimada Y; Yoneya S
Retina; 2009; 29(10):1450-6. PubMed ID: 19816240
[TBL] [Abstract][Full Text] [Related]
8. External-beam radiation therapy for age-related macular degeneration: two years' follow-up results at a total dose of 20 Gy in 10 fractions.
Churei H; Ohkubo K; Nakajo M; Hokotate H; Baba Y; Ideue J; Miyagawa K; Nakayama H; Hiraki Y; Kitasato T; Yabe N
Radiat Med; 2004; 22(6):398-404. PubMed ID: 15648455
[TBL] [Abstract][Full Text] [Related]
9. Macular microcirculation blood flow in patients with age related macular degeneration treated with photodynamic therapy and transpupillary thermotherapy.
Kubicka-Trzaska A
Klin Oczna; 2007; 109(4-6):138-41. PubMed ID: 17725271
[TBL] [Abstract][Full Text] [Related]
10. Strontium plaque brachytherapy for exudative age-related macular degeneration: three-year results of a randomized study.
Jaakkola A; Heikkonen J; Tommila P; Laatikainen L; Immonen I
Ophthalmology; 2005 Apr; 112(4):567-73. PubMed ID: 15808245
[TBL] [Abstract][Full Text] [Related]
11. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.
Rosenfeld PJ; Schwartz SD; Blumenkranz MS; Miller JW; Haller JA; Reimann JD; Greene WL; Shams N
Ophthalmology; 2005 Jun; 112(6):1048-53. PubMed ID: 15885778
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic treatment of age-related macular degeneration report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients.
Friberg TR; Musch DC; Lim JI; Morse L; Freeman W; Sinclair S;
Ophthalmology; 2006 Apr; 113(4):622.e1. PubMed ID: 16581422
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of choroidal neovascularization in the complications of age-related macular degeneration prevention trial.
Maguire MG; Alexander J; Fine SL;
Ophthalmology; 2008 Sep; 115(9):1468-73, 1473.e1-2. PubMed ID: 18486222
[TBL] [Abstract][Full Text] [Related]
14. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
15. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration.
Ahlers C; Golbaz I; Stock G; Fous A; Kolar S; Pruente C; Schmidt-Erfurth U
Ophthalmology; 2008 Aug; 115(8):e39-46. PubMed ID: 18675694
[TBL] [Abstract][Full Text] [Related]
16. Regulation of subfoveal choroidal blood flow in age-related macular degeneration.
Pournaras CJ; Logean E; Riva CE; Petrig BL; Chamot SR; Coscas G; Soubrane G
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1581-6. PubMed ID: 16565395
[TBL] [Abstract][Full Text] [Related]
17. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
Heier JS; Antoszyk AN; Pavan PR; Leff SR; Rosenfeld PJ; Ciulla TA; Dreyer RF; Gentile RC; Sy JP; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):633.e1-4. PubMed ID: 16483659
[TBL] [Abstract][Full Text] [Related]
18. Pathology beyond neovascularization: new targets in age-related macular degeneration.
Heier JS
Retina; 2009 Jun; 29(6 Suppl):S39-41. PubMed ID: 19553799
[TBL] [Abstract][Full Text] [Related]
19. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration.
Shah AR; Del Priore LV
Ophthalmology; 2009 Oct; 116(10):1901-7. PubMed ID: 19592101
[TBL] [Abstract][Full Text] [Related]
20. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
